New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:37 EDTNSTGNanoString reports preliminary Q4 revenue about $10.1M, consensus $9.61M.
NanoString anticipates instrument revenue of approximately $5.3M for Q4, representing approximately 112% growth compared to $2.5M for 4Q12. The company's installed base of nCounter Analysis Systems stood at over 180 systems as of the end of 2013. Consumables revenue is anticipated to be approximately $4.4M in Q4, representing approximately 19% growth over the $3.7M reported for 4Q12.
News For NSTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
16:07 EDTNSTGNanoString updates Prosigna FDA labeling
NanoString Technologies announced that the FDA has cleared a labeling update for the Prosigna Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8, or ABCSG-8, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive, or ER+, early-stage breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use